Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

ClinicalTrials.gov ID: NCT00234507

Public ClinicalTrials.gov record NCT00234507. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II, Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection, of Three Doses of Dysport (40 Units/Eye, 80 Units/Eye, and 120 Units/Eye) for the Treatment of Benign Essential Blepharospasm

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.

Study identification

NCT ID
NCT00234507
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ipsen
Industry
Enrollment
120 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2002
Primary completion
May 24, 2004
Completion
May 24, 2004
Last update posted
Jul 28, 2019

2003 – 2004

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Banner Health Research Institute Phoenix Arizona 85006
Neurological Institute Phoenix Arizona 85013
The Parkinson's and Movement Disorder Institute Fountain Valley California 92708
UCLA/Jules Stein Eye Institute Los Angeles California 90095
McKnight Brain Institute Gainesville Florida 32610
Plastic Eye Surgery Association Pensacola Florida 32504
Rush Presbyterian/St Luke's Medical Center Chicago Illinois 60612
Kellogg Eye Center Ann Arbor Michigan 48105
Columbia-Presbyterian Medical Center New York New York 10032
Duke University Medical Center Durham North Carolina 27705
Ophthlamic Surgeons and Consultants of Ohio, Inc Columbus Ohio 43215
Wills Eye Hospital Philadelphia Pennsylvania 19107
Parkinson's Disease Center and Movement Disorders Clinic Houston Texas 77030
Center for Facial Appearances Salt Lake City Utah 84102

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00234507, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 28, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00234507 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →